https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438995/

https://bjanaesthesia.org/article/S0007-0912(20)30563-8/fulltext

Epigenetic susceptibility to severe respiratory viral infections: pathogenic and therapeutic implications: a narrative review

• The authors reviewed the literature and ongoing clinical trials, and show that epigenetic biomarkers may stratify the risk of severe respiratory infection.
• As deoxyribonucleic acid methylation can be reversed, at least partially, some drugs (curcumin, apabetalone, and repurposed drugs such as statins and tocilizumab) may contribute to better treatment of such patients by interfering with epigenetic pathways.
• Tabke 4 lists Apabetalone with primary pro-inflammatory/cytokine storm target of ACE2
• Under "De Novo Epidrugs"  - "Apabetalone - An international consortium of scientists has identified 50 proteins as putative drug targets against COVID-19. Amongst these targets, bromodomain (BRD) 2/4 would be relevant during interaction with the (E) envelope proteins of SARS-CoV-2 and viral reproduction.94 By mimicking the histone structure, the (E) envelope proteins might potentially disrupt BRD-histone complexes. BRD proteins are epigenetic players that bind acetylated groups on histone proteins to aid in the recruitment of transcriptional machinery at promoter genes. Apabetalone can directly inhibit BET2/4 protein–SARS-CoV-2 interaction and may downregulate the expression of ACE2 receptors, which are exploited by the surface S glycoprotein to enter into human cells.101 Currently, apabetalone is not approved by FDA, but has already shown clinical safety as demonstrated during the Phase 3 trial (BETonMACE) focusing on secondary prevention of cardiovascular dysfunction in diabetics.102 Overall, this evidence suggests that apabetalone may potentially reduce viral infection and replication. In this way, Resverlogix Corporation (https://bit.ly/2CBaEKB) invites collaborators for further research on apabetalone as a putative therapeutic strategy for COVID-19."
• Under "Concluding Remarks" - " Clinical treatment of mild forms of COVID-19 should not be phobic from fever, which can promote an effective immune response and virus clearance from the body.130 Ongoing controlled clinical trials would clarify the repositioning of TCZ, whereas curcumin, apabetalone, metformin, and statins could be an effective treatment to protect innate immune response against severe viral respiratory infections. In the era of network medicine, predictive analysis tools are playing a relevant role in addressing the COVID-19 pandemic by providing maps of human proteins interacting with SARS-CoV-2 proteins101 and a list of candidate repurpose drugs and potential drug combinations targeting SARS-CoV-2.131 The epigenetic susceptibility to pulmonary viral infections requires further investigation by using the network-oriented analysis to clarify the molecular routes underlying perturbation of the human interactome,132 in particular in COVID-19 and its impact on cardiovascular health."